298 related articles for article (PubMed ID: 24225327)
1. Eslicarbazepine acetate: an update on efficacy and safety in epilepsy.
Verrotti A; Loiacono G; Rossi A; Zaccara G
Epilepsy Res; 2014 Jan; 108(1):1-10. PubMed ID: 24225327
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of eslicarbazepine: current evidence.
Zaccara G; Giovannelli F; Cincotta M; Carelli A; Verrotti A
Drug Des Devel Ther; 2015; 9():781-9. PubMed ID: 25709402
[TBL] [Abstract][Full Text] [Related]
3. Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug.
Doeser A; Dickhof G; Reitze M; Uebachs M; Schaub C; Pires NM; Bonifácio MJ; Soares-da-Silva P; Beck H
Brain; 2015 Feb; 138(Pt 2):371-87. PubMed ID: 25472797
[TBL] [Abstract][Full Text] [Related]
4. Eslicarbazepine acetate for partial-onset seizures.
Rauchenzauner M; Luef G
Expert Rev Neurother; 2011 Dec; 11(12):1673-81. PubMed ID: 22091592
[TBL] [Abstract][Full Text] [Related]
5. Eslicarbazepine acetate: A novel agent for the adjunctive treatment of epilepsy.
Owen RT
Drugs Today (Barc); 2010 Jan; 46(1):23-31. PubMed ID: 20200693
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.
Patsalos PN; Berry DJ
Expert Opin Pharmacother; 2012 Apr; 13(5):699-715. PubMed ID: 22404663
[TBL] [Abstract][Full Text] [Related]
7. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.
Ben-Menachem E; Gabbai AA; Hufnagel A; Maia J; Almeida L; Soares-da-Silva P
Epilepsy Res; 2010 May; 89(2-3):278-85. PubMed ID: 20299189
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy.
Banach M; Borowicz KK; Czuczwar SJ
Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):639-48. PubMed ID: 25740561
[TBL] [Abstract][Full Text] [Related]
9. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A
Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P;
Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Exposure-Response Analyses of Eslicarbazepine Acetate Efficacy and Safety in Monotherapy of Partial-Onset Seizures.
Sunkaraneni S; Ludwig EA; Passarell JA; Blum D; Grinnell T; Fiedler-Kelly J
J Clin Pharmacol; 2018 Jul; 58(7):927-938. PubMed ID: 29528499
[TBL] [Abstract][Full Text] [Related]
12. Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study.
Correia FD; Freitas J; Magalhães R; Lopes J; Ramalheira J; Lopes-Lima J; Chaves J
Epilepsy Res; 2014 Oct; 108(8):1399-405. PubMed ID: 25060997
[TBL] [Abstract][Full Text] [Related]
13. Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures.
Galiana GL; Gauthier AC; Mattson RH
Drugs R D; 2017 Sep; 17(3):329-339. PubMed ID: 28741150
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses.
Falcão A; Fuseau E; Nunes T; Almeida L; Soares-da-Silva P
CNS Drugs; 2012 Jan; 26(1):79-91. PubMed ID: 22171585
[TBL] [Abstract][Full Text] [Related]
15. Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.
Shorvon SD; Trinka E; Steinhoff BJ; Holtkamp M; Villanueva V; Peltola J; Ben-Menachem E
J Neurol; 2017 Mar; 264(3):421-431. PubMed ID: 28101651
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapy of epilepsy: newly approved and developmental agents.
Stephen LJ; Brodie MJ
CNS Drugs; 2011 Feb; 25(2):89-107. PubMed ID: 21254787
[TBL] [Abstract][Full Text] [Related]
17. Novel medications for epilepsy.
Fattore C; Perucca E
Drugs; 2011 Nov; 71(16):2151-78. PubMed ID: 22035515
[TBL] [Abstract][Full Text] [Related]
18. Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience.
Gama H; Vieira M; Costa R; Graça J; Magalhães LM; Soares-da-Silva P
Drug Saf; 2017 Dec; 40(12):1231-1240. PubMed ID: 28752473
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.
Trinka E; Ben-Menachem E; Kowacs PA; Elger C; Keller B; Löffler K; Rocha JF; Soares-da-Silva P
Epilepsia; 2018 Feb; 59(2):479-491. PubMed ID: 29369348
[TBL] [Abstract][Full Text] [Related]
20. [Eslicarbazepine acetate: a novel therapeutic alternative in the treatment of focal seizures].
Mauri-Llerda JA
Rev Neurol; 2012 May; 54(9):551-5. PubMed ID: 22532219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
